Bioelectric pro

Galvani Bioelectronics, the developer of bioelectronic medicines launched by GlaxoSmithKline and Alphabet’s life science play Verily (formerly Google Life Sciences) in early August, will have a bio­electronic visionary on board. Moncef Slaoui, who expedited GSK investments in the field of bioelectronics, will be the chairman of the new company’s Board of Directors.

ADVERTISEMENT

Slaoui currently serves as GSK’s Chairman of Global Vaccines and previously was Chairman of GSK R&D. He holds a PhD in Molecular Biology and Immunology from Brussels University and was a professor of Immunology at the Belgian University of Mons. He is a member of the PhRMA Foundation Board of Directors, National Institutes of Health Advisory Committee to the Director, and the Biotechnology Industry Organization Board of Directors.

YOU DON`T WANT TO MISS ANYTHING?

Sign up for our newsletter!